Xtant Medical Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Targeting major growth in orthobiologics and hemostasis, the company expanded its sales force and product lines, divested non-core assets, and expects to generate cash by Q4. Recent acquisitions and innovation support a diversified, high-margin portfolio.
-
Q2 2026 revenue declined year-over-year due to asset sales and amnio headwinds, with gross margin and profitability also down. Expanded sales force and new products like HEMOBLAST and Trivium Shaped are expected to drive growth in the second half, though full-year guidance was modestly reduced.
-
Q1 2026 revenue was $20.9M, with a net loss of $3.1M, reflecting divestitures and market headwinds. Full-year revenue guidance was raised to $101M–$105M, driven by new product launches and expanded sales force, with gross margin expected to recover in the second half.
-
Strong growth and profitability were driven by vertical integration, product innovation, and strategic divestitures. Expanded product lines and new market entries, including OEM and wound care, support future growth, while a strengthened balance sheet and operational focus position the company for continued success.
Fiscal Year 2025
-
Revenue grew 14% in 2025 to $133.9M, with strong gross margin and a return to profitability. 2026 guidance reflects divestitures and non-recurring revenue loss, but core biologics is expected to accelerate as new products and expanded sales force drive growth.
-
Q3 2025 saw 19% revenue growth to $33.3M, improved gross margin, and a return to profitability, driven by licensing and biologics. Pending sale of non-core assets will enhance liquidity and focus, with 2025 revenue guidance reiterated at $131–$135M.
-
The presentation highlighted strong growth, improved profitability, and a sharpened focus on core orthobiologics through divestitures and vertical integration. New product launches and a robust pipeline support expansion into adjacent markets, with no need for additional capital.
-
A high-growth, vertically integrated medtech firm is focusing on regenerative biologics, divesting non-core assets, and expanding its product pipeline with innovations like Trivium and collagen-based products. Strong financials, broad commercial reach, and diversification support future growth.
-
Q2 2025 saw 18% revenue growth, improved gross margin, and a return to profitability, driven by strong biologics performance and licensing revenue. Full-year guidance was raised, and the sale of non-core assets will further strengthen focus and liquidity.
-
Q1 2025 saw 18% revenue growth to $32.9M, driven by biologics, with a return to profitability and improved margins from vertical integration. FY 2025 guidance was raised to $127–$131M, with strong biologics growth expected and no new capital needed.
Fiscal Year 2024
-
Record Q4 and full-year revenue were driven by strong biologics growth and Surgalign integration, with cost reductions and operational efficiencies improving cash flow. 2025 guidance projects 8–11% revenue growth, margin improvement, and no need for additional capital.
-
Q3 2024 saw 12% revenue growth and reaffirmed full-year guidance, despite product launch delays and seasonal softness. Margin expansion and profitability are expected as in-house manufacturing and OEM channels grow, with new products and a major licensing deal set to drive Q4 and 2025.
-
A diversified orthobiologics and spinal hardware company is leveraging a broad product portfolio, recent acquisitions, and a robust distribution network to drive strong growth and margin expansion. Management expects continued double-digit growth, improved profitability, and sees the business as significantly undervalued.
-
Q2 2024 saw 48% revenue growth, driven by Surgalign acquisitions and new product launches. Guidance for 2024 was reaffirmed, with expectations for accelerating organic growth and positive operating cash flow by Q4. Gross margins and cash position remain stable.